Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

PRINTO (the Paediatric Rheumatology International Trials Organisation)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by Institute of Child Health.
Recruitment status was  Recruiting
Information provided by:
Institute of Child Health Identifier:
First received: December 22, 2006
Last updated: December 23, 2006
Last verified: December 2006

A comparison of outcome in children with JIA who are in remission on MTX, when MTX is then stopped for either 6 or 12 months

Condition Intervention
Juvenile Idiopathic Arthritis
Drug: methotrexate

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal

Resource links provided by NLM:

Further study details as provided by Institute of Child Health:

Estimated Study Completion Date: December 2006

Ages Eligible for Study:   up to 16 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Any child with JIA who has gone into remission using methotrexate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00415935

Contact: Lucy Wedderburn, Dr

United Kingdom
Rheumatology ICH Recruiting
London, United Kingdom, WC1N 1EH
Contact: Lucy Wedderburn, Dr   
Sponsors and Collaborators
Institute of Child Health
Principal Investigator: Lucy Wedderburn, Dr Institute Of Child Health and Great Ormond Street Hospital
  More Information

No publications provided Identifier: NCT00415935     History of Changes
Other Study ID Numbers: 04RU01
Study First Received: December 22, 2006
Last Updated: December 23, 2006
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Arthritis, Juvenile
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on November 24, 2014